New Analyst Forecast: $AFYA Given $18 Price Target

UBS analyst Andre Salles has set an $18 price target for AFYA, aligning with the median target from three analysts over the last six months. Other analysts like Marcelo Santos (JP Morgan) and Leandro Bastos (Citigroup) have differing targets of $22 and $14, respectively. The article also notes recent institutional investor activity for AFYA stock, with some institutions increasing their positions and others decreasing them.

Original reporting
Quiver Quantitative · Quiver ForecastTracker
Published Jan 9, 2026, 2:10 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jan 9, 2026, 2:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
New Analyst Forecast: $AFYA Given $18 Price Target — source image
Decision brief

The 30-second read

$AFYANeutralMed
01

Why it matters

The analyst target and institutional activity could influence short-term trading, but the overall impact remains moderate due to mixed signals.

02

Market read

The news has moderate relevance for traders focusing on healthcare stocks, especially those with short-term trading horizons.

03

What to watch

Potential upcoming earnings reports or sector developments could significantly alter the outlook, which are not addressed in this news.

Timing: Immediate, as the news is recent and may influence short-term trading decisions.

Background

AFYA is a healthcare company with recent analyst coverage and institutional activity, indicating ongoing interest and evaluation by market participants.

Company-level read

Ticker impact

$AFYANeutralMedium confidence
Context

The news pertains directly to AFYA, a healthcare company, with a new analyst price target and recent institutional activity, indicating potential trading implications.

Expected impact

Potential slight upward movement in the short term, contingent on market reaction to analyst consensus and institutional activity.

Evidence & confidence

The consensus target and institutional activity suggest a cautiously optimistic outlook, but divergent analyst targets and limited recent price data introduce uncertainty.

Market effects

The healthcare sector may experience slight positive sentiment, but overall impact is limited due to the news's company-specific nature.

Minimal, as the news pertains primarily to a U.S.-listed company with no broader regional implications.

Negligible, given the localized focus and limited industry-wide impact.

Counterpoint

The divergence in analyst targets and limited recent price momentum suggest the stock may underperform if negative news or broader market downturns occur.

Key entities

  • UBS

    UBS analyst Andre Salles issued the $18 price target.

  • AFYA

    Healthcare company subject to the analyst forecast and institutional activity.

Related articles

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.

$NOCMed

WP: Pentagon asks defense companies to urgently ramp up weapons production

The Pentagon, via Deputy Secretary Steve Feinberg, urged U.S. defense firms to accelerate weapons output, especially ammunition, and asked executives to submit production and delivery plans within 21 days, according to The Washington Post. CSIS data cited Patriot and THAAD stockpiles falling sharply. The article notes talks with Northrop Grumman and Lockheed Martin and a Lockheed contract up to $58.6B to triple PAC-3 output by 2030.